Imbruvica (ibrutinib)
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
June 2016
ADVERSE REACTIONS
Postmarketing Experience
(Addition) Respiratory disorders: interstitial lung disease (includes...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts